Fintel on MSN

Genmab A (GMAB) Price Target Decreased by 11.19% to 55.27

The average one-year price target for Genmab A (NasdaqGS:GMAB) has been revised to $55.27 / share. This is a decrease of ...
BioSpace

FDA Action Alert: BMS, Bayer, Arrowhead and More

One of the FDA’s potential approvals this month could break an existing monopoly in the treatment space for a rare growth ...

Does Genmab’s Robust Q3 and Upbeat Outlook Reinforce the Bull Case for CPSE:GMAB?

In its most recent quarterly report, Genmab A/S posted strong results, with third quarter sales reaching US$1.02 billion and net income more than doubling compared to a year earlier. The company also ...
TipRanks on MSN

Genmab’s Earnings Call: Strong Growth Amid Challenges

Genmab (Otc) (($GMAB)) has held its Q3 earnings call. Read on for the main highlights of the call. Genmab’s recent earnings call painted a ...

Genmab Provides Certain Information Disclosed in Connection with Proposed Private Offering of Senior Secured Notes and Senior Unsecured Notes

Media Release COPENHAGEN, Denmark; November 10, 2025 Genmab A/S (“Genmab”) announced on November 10, 2025, that it and its wholly owned subsidiary Genmab Finance LLC intend to offer, subject to market ...
Santé log

Genmab Announces Proposed Private Offering of Senior Secured Notes and Senior Unsecured Notes and Syndication of New Senior Secured Term Loan Facility

Genmab A/S (Nasdaq: GMAB) (“Genmab”) announced today that it and its wholly owned subsidiary Genmab Finance LLC (“Genmab Finance”) intend to offer, subject to market and other conditions, $1.5 billion ...